Press release
Angina Pectoris Treatment Market Stand Out As The Biggest Contributor In Healthcare
Angina pectoris is a medical term for chest pain or discomfort, which is caused due to coronary heart disease. Angina pectoris mainly occurs when heart muscle are unable to receive adequate blood. This condition usually occurs when one or more of the heart’s arteries are narrowed or blocked, which is also known as ischemia. Angina pectoris leads to uncomfortable pressure, fullness, squeezing or pain in the center of the chest. The factors that trigger stable angina pectoris include, emotional stress, exposure to very hot or cold temperature, heavy meals or smoking. Angina pectoris can be diagnosed by an electrocardiogram and angiography and could be treated by medication, change in life style, and surgery. A minimal invasive procedure known as angioplasty is also used to treat the angina pectoris. The pain or discomfort caused by angina pectoris is relieved with rest and nitroglycerin. Nitroglycerin relaxes the coronary arteries and other blood vessels by increasing the blood flow to the heart vessels.Angina Pectoris Treatment Market Taxonomy
By Drug Class:
Beta blockers
Calcium channel blockers
Nitrates
Angiotensin-converting enzyme inhibitors
Other
By Indication:
Stable Angina
Unstable Angina
Get HOLISTIC Request Sample Copy Of This Business Report:
https://www.coherentmarketinsights.com/insight/request-sample/1158
New product launches and strong pipeline is expected to fuel the growth of angina pectoris treatment market
Espero announced in June 2016, that the company received approval from the U.S. Food and Drug Administration (FDA) for GoNitro (nitroglycerin) sublingual powder for acute relief of an attack or prophylaxis of angina pectoris, due to coronary artery disease. In February 2016, AstraZeneca sold the rights of its two medicines Plendil and Imdur for US $500Mn. China Medical System Holdings (CMS) agreed to pay AstraZeneca US $310 million for commercialization rights of Plendil (felodipine) in China. Plendil is a calcium antagonist indicated for both hypertension and the prophylaxis of the chronic stable angina pectoris. Whereas, Imdur is an oral extended-release formulation of isosorbide mononitrate indicated for the prevention of angina pectoris, due to coronary artery disease.
Furthermore, Amgen offers a product named Corlanor (Ivabradine) for the treatment of angina pectoris in its pipeline (phase 3), which was presented by the company in year 2015 at Annual Scientific Session. In November 2016, Allergan also presented new data on BYSTOLIC (nebivolol) for the treatment of hypertension to lower blood pressure at the Annual American Heart Association Meeting in New Orleans. Whereas, Perrigo announced FDA approval of its abbreviated new drug application (ANDA) for Nitroglycerin Lingual Spray in 2013, the generic version of Shionogi's Nitrolingual Pumpspray indicated for acute attacks and prophylaxis of angina pectoris.
Strategic activities by market players to increase their market share
Angina pectoris treatment market is driven by factors, such as increasing number of collaborations, product launches, and mergers and acquisition. For instance, Recordati acquired AstraZeneca blood pressure brand Metoprolol, in 2017, which is a beta-blocker used mainly for the conditions, such as angina pectoris, hypertension, and heart disorders. Furthermore, Pharmaceutical manufacturer Lupin received approval from U.S. FDA in 2017 to launch the generic version of the U.S WorldMeds’ nadolol drug indicated for the patients with angina pectoris and for the treatment of hypertension. Moreover, patent expiry of Ranolazine drug from Gilead Sciences, Inc. in 2019 would mark the opportunity for generic drug manufacturers in the global angina pectoris treatment market.
Download the PDF brochure:
https://www.coherentmarketinsights.com/insight/request-pdf/1158
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Contact Us:
Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:sales@coherentmarketinsights.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Angina Pectoris Treatment Market Stand Out As The Biggest Contributor In Healthcare here
News-ID: 1617301 • Views: …
More Releases from Coherent Market Insights

Poppy Seeds Market 2032 Industry Overview, Evolution Growth Rate and Future Fore …
The Poppy Seeds market is estimated to be valued at USD 341.3 Mn in 2025 and is expected to reach USD 506.8 Mn by 2032, growing at a compound annual growth rate CAGR of 5.8% from 2025 to 2032.
➤ The latest study, of the global Poppy Seeds Market presents an in-depth evaluation of current market dynamics, key players, regional trends, market segments, applications, and growth opportunities, with forecasts extending from…

Global Supply Chain Security Market Size 2025 Emerging Demands, Share, Trends, F …
The Global Supply Chain Security Market is estimated to be valued at USD 2.64 Bn in 2025 and is expected to reach USD 5.62 Bn by 2032, exhibiting a compound annual growth rate (CAGR) of 11.4% from 2025 to 2032.
The latest research study released by Coherent Market Insights on "Supply Chain Security Market 2025 Forecast to 2032" research provides accurate economic, global, and country-level predictions and analyses. It provides a…

Global Mobile Cloud Market Size 2025 Emerging Demands, Share, Trends, Futuristic …
The Global Mobile Cloud Market is estimated to be valued at USD 72.43 Bn in 2025 and is expected to reach USD 284.74 Bn by 2032, exhibiting a compound annual growth rate (CAGR) of 21.6% from 2025 to 2032.
The latest research study released by Coherent Market Insights on "Mobile Cloud Market 2025 Forecast to 2032" research provides accurate economic, global, and country-level predictions and analyses. It provides a comprehensive perspective…

Vendor Management Systems Market Share & Growth 2025: Investment Opportunities a …
The Global Vendor Management Systems Market is estimated to be valued at USD 10.42 Bn in 2025 and is expected to reach USD 20.69 Bn by 2032, exhibiting a compound annual growth rate (CAGR) of 10.30% from 2025 to 2032.
The latest research study released by Coherent Market Insights on "Vendor Management Systems Market 2025 Forecast to 2032" research provides accurate economic, global, and country-level predictions and analyses. It provides a…
More Releases for Angina
Angina (Angina Pectoris) Pipeline: 10+ Companies Transforming Chest Pain Managem …
The angina therapeutics pipeline is experiencing a renaissance, driven by pharmaceutical companies such as Abbott Laboratories, AstraZeneca, Bayer AG, and Bristol-Myers Squibb. With a focus on improving myocardial efficiency and reducing ischemic burden, emerging therapies-including metabolic modulators, nitric oxide donors, and gene therapies-aim to offer more effective symptom relief and reduce cardiovascular events. Innovations are targeting both stable and microvascular angina forms, addressing the significant unmet needs in chronic angina…
Key Influencer in the Angina Pectoris Drugs Market Outlook 2025: Surging Prevale …
What market dynamics are playing a key role in accelerating the growth of the angina pectoris drugs market?
The surge in cardiovascular diseases is anticipated to kick-start the expansion of the angina pectoris drug market. The scope of cardiovascular diseases includes diverse disorders affecting the heart and blood vessels, such as stroke, coronary artery disease, hypertension, and heart failure. The rising prevalence of cardiovascular diseases (CVD) is linked to numerous elements,…
What's Driving the Angina Market 2025-2034: The Rising Prevalence of Coronary Ar …
What Are the Projections for the Size and Growth Rate of the Angina Market?
The scale of the angina market has seen robust growth in the previous years. The expansion is expected to continue, increasing from a value of $10.71 billion in 2024 to $11.4 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 6.4%. The surge in the past period can be credited to factors such as a…
Angina Pectoris - Drug Pipeline Landscape, 2022
Global Angina Pectoris Market report from Global Insight Services is the single authoritative source of intelligence on angina pectoris market. The report will provide you with analysis of impact of latest market disruptions such as Russia-Ukraine war and Covid-19 on the market. Report provides qualitative analysis of the market using various frameworks such as Porters' and PESTLE analysis. Report includes in-depth segmentation and market size data by categories, product types,…
Angina Pectoris - Drug Pipeline Landscape, 2022
Angina also known as angina pectoris, is a type of chest pain or discomfort that occurs when a part of the heart doesn't get enough blood and oxygen, which is due to the spasm or obstruction of the arteries that supply the blood to the heart muscles. Angina is mainly of four types: stable angina, unstable angina, microvascular angina, and vasospastic or variant angina.
Angina is caused due to the built…
Angina Pectoris Drugs Market Set for Rapid Growth
Global Angina Pectoris Drugs Market: Overview
The demand within the global market for angina pectoris drugs has been rising on account of the focus given on treating medical conditions suffered by the geriatric population. The presence of a seamless industry for healthcare diagnostic and treatment has played a major role in market growth. Angina pectoris is a type of chest pain that is triggered due to reduced blood flow to…